Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Genetics Completes $14M Purchase of Response Genetics' Assets

NEW YORK (GenomeWeb) – Cancer Genetics today announced it has completed the $14 million purchase of the assets of Response Genetics. 

Response Genetics filed for Chapter 11 bankruptcy protection in August. At the time, the Los Angeles-based cancer molecular diagnostics firm also said that it had entered into a stalking horse agreement for substantially all of its assets to be purchased by Cancer Genetics. A US Bankruptcy Court approved the acquisition earlier this month.

The deal is expected to provide Cancer Genetics between $10 million and $12 million in revenues. The company also said that it is expected to provide $4 million in future contract value from biopharma and clinical research clients. Cancer Genetics said it will continue to grow Response Genetics' biopharma operations, as well as its clinical services. 

Additionally, Cancer Genetics will take over Response Genetics' ALCHEMIST trial contract, which was awarded by the National Institutes of Health last year and will use tumor sequencing and genetic markers to determine whether therapies targeting genetic alterations can prevent lung cancer recurrence.

Alan Cheeks, Response Genetics' vice president of operations, will join Cancer Genetics’ management and be responsible for the company's day-to-day clinical and biopharma operations. Additionally, more than 20 sales people from Response Genetics will join the Rutherford, New Jersey-based company. 

Cancer Genetics paid $7 million in cash and 788,584 shares of ist common stock to complete the deal.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.